(Q37882225)

24 August 2017

1 reference

title

Screening for type 2 diabetes and dysglycemia (English)

1 reference

24 August 2017

0 references

3

1 reference

24 August 2017

Justin B Echouffo-Tcheugui

series ordinal

1

1 reference

24 August 2017

Mohammed K Ali

series ordinal

2

1 reference

24 August 2017

K M Venkat Narayan

series ordinal

4

1 reference

24 August 2017

30 May 2011

1 reference

24 August 2017

Epidemiologic Reviews

1 reference

24 August 2017

33

1 reference

24 August 2017

63-87

1 reference

The prevention of type 2 diabetes

24 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Standards of medical care in diabetes--2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for Type 2 diabetes--should it be now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes: literature review and economic modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Early detection of undiagnosed diabetes mellitus: a US perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The value of early detection of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening and diagnosis of prediabetes: where are we headed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of diabetes among men and women in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Mortality attributable to diabetes: estimates for the year 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The evolving diabetes burden in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Global healthcare expenditure on diabetes for 2010 and 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Economic costs of diabetes in the U.S. In 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The economic costs of undiagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Subclinical states of glucose intolerance and risk of death in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Microvascular complications of impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The spectrum of neuropathy in diabetes and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Higher medical care costs accompany impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Medical cost associated with prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The natural history of impaired glucose tolerance in the Pima Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Pathophysiology of prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of an NIDDM screening questionnaire based on symptoms and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The diabetes risk score: a practical tool to predict type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A Danish diabetes risk score for targeted screening: the Inter99 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Development and validation of a patient self-assessment score for diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Do simple questions about diet and physical activity help to identify those at risk of Type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A prediction model for type 2 diabetes risk among Chinese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Community-based screening for diabetes in Michigan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Derivation and validation of diabetes risk score for urban Asian Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A risk score for predicting incident diabetes in the Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Predicting impaired glucose tolerance using common clinical information: data from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

An accurate risk score for estimation 5-year risk of type 2 diabetes based on a health screening population in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross-sectional population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Genotype score in addition to common risk factors for prediction of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Clinical risk factors, DNA variants, and the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Using metabolic syndrome traits for efficient detection of impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Derivation and external validation of a simple prediction model for the diagnosis of type 2 diabetes mellitus in the Brazilian urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A multivariate logistic regression equation to screen for dysglycaemia: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A simple Chinese risk score for undiagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Risk scores for type 2 diabetes can be applied in some populations but not all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A new look at screening and diagnosing diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The utility of fasting glucose for detection of prediabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A1C and diabetes diagnosis: The Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of HbA(1c) for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A1C cut points to define various glucose intolerance groups in Asian Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Approved IFCC reference method for the measurement of HbA1c in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Glucose challenge test screening for prediabetes and undiagnosed diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Point-of-care testing as a tool for screening for diabetes and pre-diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevention of type 2 diabetes: risk status, clinic, and community

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Sick individuals and sick populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Determinants of healthy eating: motivation, abilities and environmental opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Toward the reduction of population obesity: macrolevel environmental approaches to the problems of food, eating, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Glucose screening and the risk of complications in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Impact of diabetes screening on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for Type 2 diabetes: an exploration of subjects' perceptions regarding diagnosis and procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The impact of screening for Type 2 diabetes in siblings of patients with established diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Diabetes screening anxiety and beliefs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

No substantial psychological impact of the diagnosis of Type 2 diabetes following targeted population screening: The Hoorn Screening Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Are lifestyle changes achieved after participation in a screening programme for Type 2 diabetes? The ADDITION Study, Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Psychological effects of prevention: do participants of a type 2 diabetes prevention program experience increased mental distress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for Type 2 diabetes mellitus: a decision analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

What determines the cost-effectiveness of diabetes screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Economic evaluation of alternative indicators for screening for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Using an economic model of diabetes to evaluate prevention and care strategies in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening adults for pre-diabetes and diabetes may be cost-saving

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Training YMCA wellness instructors to deliver an adapted version of the Diabetes Prevention Program lifestyle intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Opportunistic screening for diabetes in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Irish diabetes detection programme in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Yield of opportunistic targeted screening for type 2 diabetes in primary care: the diabscreen study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for diabetes in an outpatient clinic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for diabetes in general practice: cross sectional population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Assessment of diabetes screening by general practitioners in France: the EPIDIA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for pre-diabetes and diabetes in the workplace

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Characteristics of undiagnosed diabetes mellitus in a population undergoing health screening in Japan: target populations for efficient screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Community-based screening for cardiovascular disease and diabetes using HbA1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Sequential screening for diabetes--evaluation of a campaign in Swiss community pharmacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of recommended screening tests for undiagnosed diabetes and dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Performance of a predictive model to identify undiagnosed diabetes in a health care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

The European Perspective of Type 2 Diabetes Prevention: Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention (DE-PLAN) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Outcomes of screening for diabetes in high-risk Hong Kong Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEPIREV%2FMXQ020

21 January 2018

Identifiers

DOI

10.1093/EPIREV/MXQ020

1 reference

release_7mvxgesbcbfa7fbqg5riwxbaha

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7mvxgesbcbfa7fbqg5riwxbaha

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference